You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Novartis says its radioligand therapy boosts health-related quality of life

Swiss pharma company Novartis has reported positive health-related quality of life (HRQoL) data from a late-stage study evaluating its radioligand therapy 177Lu-PSMA-617.